Synergistic effects of depression and NR3C1 methylation on prognosis of acute coronary syndrome by Kang, Hee Ju et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1038/s41598-020-62449-2
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Kang, H. J., Stewart, R., Kim, J. W., Kim, S. W., Shin, I. S., Kim, M. C., ... Kim, J. M. (2020). Synergistic effects
of depression and NR3C1 methylation on prognosis of acute coronary syndrome. Scientific Reports, 10(1),
[5519]. https://doi.org/10.1038/s41598-020-62449-2
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 12. May. 2020
1Scientific RepoRtS |         (2020) 10:5519  | https://doi.org/10.1038/s41598-020-62449-2
www.nature.com/scientificreports
Synergistic effects of depression 
and NR3C1 methylation on 
prognosis of acute coronary 
syndrome
Hee-Ju Kang1, Robert Stewart2,3, Ju-Wan Kim1, Sung-Wan Kim1, Il-Seon Shin1, Min-Chul Kim4, 
Young Joon Hong4, Youngkeun Ahn4, Myung-Geun Shin  5, Myung Ho Jeong4, Jin-Sang Yoon1 
& Jae-Min Kim  1*
High levels of methylation in the GR gene (nuclear receptor subfamily 3, group C, member 1; NR3C1) 
have been associated with depression and cardiovascular risk. This study aimed to investigate whether 
NR3C1 methylation status was associated with the long-term prognosis of acute coronary syndrome 
(ACS) considering depression and cardiovascular status at the early phase of ACS. A total of 969 patients 
with recent ACS were recruited at a tertiary university hospital in Korea. Baseline evaluations were 
made from 2007 to 2012, including DSM-IV depressive disorder, NR3C1 methylation, and various 
demographic and clinical characteristics such as cardiovascular risk markers. Over a 5~12 year follow-up 
after the index ACS, time to major adverse cardiac event (MACE) was investigated using Cox regression 
models. Higher NR3C1 methylation status was associated with depression and several cardiovascular 
risk markers at baseline. NR3C1 hypermethylation predicted worse long-term prognosis of ACS only in 
the presence of depressive disorder with significant synergistic interaction terms and independent of 
potential confounding factors. Synergistic effects of depressive disorder and NR3C1 hypermethylation 
on long-term cardiac outcomes in ACS were found. NR3C1 methylation status represents a candidate 
prognostic biomarker for ACS in combination with a diagnosis of depressive disorder. Further research is 
needed to ascertain the generalisability of these findings.
Depression is common in patients with acute coronary syndrome (ACS; including myocardial infarction (MI) 
and unstable angina (UA)), and is associated with poor prognosis including increased morbidity and mortality1. 
Common biological mechanisms underlying ACS and depression may account for this2. Dysregulation of hypo-
thalamic–pituitary–adrenal (HPA) axis is one candidate, since this is strongly implicated in the pathogenesis 
of depression3 and also associated with impaired repair after cardiac injury4. The effects of cortisol, the major 
endogenous glucocorticoid hormone in the HPA axis, are principally mediated by glucocorticoid receptors 
(GRs), whose expression and sensitivity are modulated by epigenetic modifications5. DNA methylation, one of 
the widely investigated epigenetic modifications, refers to covalent methylation of the C5 position of cytosine 
residues followed by guanine residues (CpG dinucleotides)6.
High levels of methylation in the GR gene (nuclear receptor subfamily 3, group C, member 1; NR3C1) 
have been reported to be correlated with reduced GR expression in animals7, and in humans with depression8, 
post-traumatic stress disorder9, and suicidality10. With respect to ACS, hypermethylation of NR3C1 has been 
found to be associated with atherosclerosis and elevated cardiovascular reactivity11,12. Recently, our study group 
found that higher DNA methylation of NR3C1 was independently associated with depressive disorder at the early 
phase of ACS13. Based on these findings, it can be postulated that NR3C1 methylation status may be associated 
with cardiac prognosis of ACS independently of or interactively with depression. However, the role of NR3C1 
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methylation on prognosis of ACS has not been investigated, despite the clinical importance of depression-ACS 
comorbidity.
In the present study, we aimed to investigate whether NR3C1 methylation status was correlated with known 
cardiovascular markers at the early phase of ACS, and whether it was associated with the long-term prognosis of 
ACS considering the negative impact of depression on these outcomes.
Materials and Methods
Study outline and participants. The analyses were performed using data from a large naturalistic cohort 
study which was set up to investigate the inter-relationships between depression and ACS: the DEPression in 
ACS (DEPACS) study. The design and main findings have been published14,15. The outline of the recruitment 
process for the present analysis is presented in online Fig. S1. ACS patients (N = 4809), recently hospitalized at the 
Department of Cardiology of Chonnam National University Hospital, Gwangju, South Korea, were approached 
consecutively to participate in the study from 2006 to 2012. With authorization by the Korean Circulation Society, 
this department has played the role of the central coordinating centre for the Korea Acute Myocardial Infarction 
Registry (KAMIR)16.
KAMIR is a web-based registry platform (http://kamir5.kamir.or.kr/) to collect nationwide multicentre data 
regarding clinical practices and outcomes of patients with acute MI prospectively which enables it to evaluate the 
prospective associations of a range of exposures or interventions with long-term cardiac outcomes. Treatment of 
ACS patients was based on international guidelines for the management of ACS17 by cardiologists participating 
in the present study. Those who met eligibility criteria (detailed in online supplementary material) and agreed 
to participate (N = 1152) received baseline evaluations as inpatients within 2 weeks (mean 6.3 ± SD 2.4 days) 
post-ACS. Of these, 969 (84.1%) agreed to phlebotomy and comprised the study sample. All participants were 
approached for follow-up evaluations for cardiac outcomes at 2017, 5~12 years after the index ACS. Written 
informed consent was obtained, and the study was conducted in compliance with institutional guidelines and the 
1964 Declaration of Helsinki. Moreover, the present study was approved by the Chonnam National University 
Hospital (CNUH) Institutional Review Board.
Baseline evaluation. Depressive disorders were diagnosed by psychiatrists with the Mini-International 
Neuropsychiatric Interview (MINI)18, a structured diagnostic interview for psychiatric disorders, according to 
criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)19, for defining 
major or minor depressive disorders.
For NR3C1 methylation status, DNA was extracted from venous blood using standard procedures. The NR3C1 
region chosen for methylation analysis was exon 1 F (GeneBank #AY 436590), which includes a binding site for 
nerve growth factor-inducible protein A (NGFI-A) and is highly expressed in the hippocampus of pups with 
nurturing mothers20. Methylation status was measured in three CpG sites (Supplementary Fig. 2), located in the 
CpG-rich region of NR3C1 exon 1 F between −3166 and −3147 (CGGTGGCCCTCTTAACGCCG) relative to 
the translational start site (+1). These sites correspond to the region investigated in previous studies on adverse 
life experiences and related disorders including depression21–24.
Information on the features that could potentially affect cardiac outcomes25 was obtained. Demographic char-
acteristics were collected on age, gender, education, marital status, living alone, housing, and employment status. 
For depression characteristics, the score from the self-completed Beck Depression Inventory (BDI)26 and previous 
and family histories of depression were recorded. For cardiac characteristics, ACS diagnosis (MI or UA), previous 
and family histories of ACS, diagnosed hypertension and diabetes mellitus, and reported current smoking status 
were ascertained. The following cardiovascular risk markers were measured: echocardiography for left ventricular 
ejection fraction (LVEF) and wall motion; electrocardiography for heart rate, PR interval, QRS duration, and QTc 
duration; measurements of body mass index (BMI) and blood pressure; and laboratory tests for troponin I, cre-
atine kinase-MB (CK-MB), tumor necrosis factor-α, Interleukin (IL)-1β, IL-6, IL-18, high sensitivity C-reactive 
protein (hs-CRP), homocysteine, total- and lower density lipoprotein (LDL) cholesterol, and triglyceride levels.
Long-term cardiac outcomes. Long-term cardiac outcomes were comprehensively evaluated using 
KAMIR data because detailed electronic data regarding hospital admissions, deaths, recurrent MI, and percu-
taneous coronary intervention (PCI) was stored in the KAMIR registry. All baseline participants in the present 
study were followed up for these outcomes. To implement non-hierarchic endpoint analyses, all patients were 
followed for the evaluation point of interest or until death. The primary endpoint was determined as a major 
adverse cardiac event (MACE), a defining composite of all-cause mortality, MI and PCI. Secondary endpoints 
were selected as all-cause mortality, cardiac death (determined as sudden death without other causes, death from 
arrhythmias or after MI or heart failure, or death caused by heart surgery or endocarditis), MI, and PCI. All 
potential events were adjudicated by an independent endpoint committee composed of study cardiologists who 
was blinded to participants’ depression comorbidity.
Statistical analyses. Using the sample median value, NR3C1 methylation percentages were classified by a 
binary variable (‘lower’ or ‘higher’ categories), in line with previous research27. Demographic and clinical charac-
teristics of ACS patients with lower and higher methylation were compared applying t-tests or χ2 tests, as appro-
priate. Correlations between the methylation percentage and cardiovascular risk markers were examined by the 
Spearman correlation coefficients, after partial for BDI scores. Factors potentially associated with methylation status 
(p < 0.05) and other characteristics found to possess significant effects on MACE25,28 were considered as covari-
ates in subsequent adjusted analyses. Kaplan–Meier curves were constructed, and the cumulative proportions of 
MACE in those with lower vs. higher NR3C1F methylation values were compared using the log-rank tests, and 
further stratified by the presence or not of depressive disorders at baseline. Time to the first composite and individual 
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MACEs were subsequently compared using Cox proportional hazards models, after adjustment for the potential 
covariates described above, between the lower vs. higher methylation groups in total participants and then by their 
depressive disorder comorbidity status. Additional sensitivity analyses were carried out applying the methylation 
value as a continuous exposure variable (10 percent unit increase) and as tertials (lower, middle, and higher) to 
re-examine its effect beyond the binary categorical approach. Schoenfeld residuals tests were carried out to test 
proportional-hazards assumptions in all models. Two-tailed tests were used in all of analyses to determine signifi-
cance at the 5% level and all statistical analyses were conducted with SPSS 21.0 and STATA 12.0 software.
Results
NR3C1 methylation status and baseline characteristics. Of 969 participants, 378 (39%) ACS patients 
experienced depressive disorders at the baseline. Median (interquartile rage) and mean (standard deviation) value 
of average NR3C1 methylation percentages and three individual CpG sites are summarized in online Table S1. 
Since the individual three CpG sites of NR3C1 methylation percentages were closely correlated (all Spearman’s 
rho > 0.7, p-value < 0.001), the results regarding average CpG values were robust and similar but less obvious for 
individual CpG sites. Therefore, the results for average CpG values were solely presented in subsequent analyses. 
In Table 1, baseline characteristics of ACS patients with lower and higher average NR3C1 methylation values are 
compared. The mean (standard deviation) and range of lower methylation group were 12.2 (5.2) and 0–20.4% 
while those of higher group were 31.2 (9.1) and 20.4–66.0%. A higher average methylation value was only signifi-
cantly associated with higher BDI scores. No significant difference was found between those who did and did not 
agree to provide blood samples in terms of any baseline characteristic (all p-values > 0.15).
Correlations between NR3C1 methylation percentage and cardiovascular risk markers. NR3C1 
average methylation percentage was significantly correlated with longer QTc duration, higher BMI, and higher 
serum levels of troponin I and CK-MB after partial for BDI scores (Table 2). These characteristics were entered as 
covariates in the following adjusted analyses. In addition, age, ACS diagnosis, previous ACS, hypertension, dia-
betes, smoking, LVEF, and/or depressive disorders were also included as covariates because of known association 
with cardiac outcomes in previous studies25,28.
Effects of NR3C1 methylation percentage on prognosis of ACS. The cardiac outcomes of all partic-
ipants were followed until 2017 or to their deaths [median; mean (standard deviation) duration of follow-up = 
8.4; 8.7 (1.5) years]. 383 participants (39.5%) experienced the primary endpoint (composite MACE). Secondary 
endpoint numbers were as follows: 178 (18.4%) for all-cause mortality, 98 (10.1%) for cardiac death, 101 (10.4%) 
for MI and 139 (14.3%) for PCI. The cumulative risk of the composite MACE in subjects with lower and higher 
average NR3C1 methylation is described in Fig. 1. A significant difference was found in the total sample. However, 
stratified by depressive disorder status, a significant group difference was found only in those with depressive 
disorder, and did not appear to be present in those without depressive disorder.
Lower methylation 
(N = 484)
Higher methylation 
(N = 485)
Statistical 
coefficient P-valuea
Socio-demographic characteristics
Age, mean (SD) years 58.7 (11.2) 57.8 (11.0) t = +1.012 0.312
Gender, N (%) female 349 (72.1) 351 (72.4) χ2 = 0.008 0.927
Education, mean (SD) years 9.9 (4.7) 9.8 (4.6) t = +0.447 0.655
Unmarried marital status, N (%) 68 (14.0) 73 (15.1) χ2 = 0.196 0.658
Living alone, N (%) 41 (8.5) 51 (10.5) χ2 = 1.178 0.278
Housing, N (%) rented 68 (14.0) 82 (16.9) χ2 = 1.512 0.210
Currently unemployed, N (%) 179 (37.0) 189 (39.0) χ2 = 0.405 0.524
Depression characteristics
BDI, mean (SD) score 8.3 (8.0) 11.8 (8.9) t = −6.483 <0.001
Previous depression, N (%) 15 (3.1) 19 (3.9) χ2 = 0.479 0.489
Family history of depression, N (%) 15 (3.1) 8 (1.6) χ2 = 2.197 0.138
Cardiac characteristics, N (%)
ACS diagnosis
       Myocardial infarction 368 (76.0) 346 (71.3) χ2 = 2.751 0.097
       Unstable angina 116 (24.0) 139 (28.7)
Previous ACS 17 (3.5) 22 (4.5) χ2 = 0.657 0.418
Family history of ACS 14 (2.9) 17 (3.5) χ2 = 0.294 0.588
Hypertension 224 (46.3) 234 (48.2) χ2 = 0.376 0.540
Diabetes mellitus 90 (18.6 101 (20.8) χ2 = 0.761 0.383
Current smoker 174 (36.0) 192 (39.6) χ2 = 1.363 0.243
Table 1. Baseline characteristics by NR3C1 average methylation. ap-values using t-tests or χ2 tests as 
appropriate. BDI, Beck Depression Inventory; ACS, acute coronary syndrome.
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Comparisons of first MACE rates by lower vs. higher methylation values, successively adjusted for potential 
confounding variables, are summarized in Table 3. In the unadjusted analyses, a higher methylation was signifi-
cantly associated with higher rates of composite MACE, all-cause mortality, MI, and PCI. The associations were 
weaker and remained significant only for composite MACE and MI outcomes after adjustment for age, ACS diag-
nosis, previous ACS, hypertension, diabetes, smoking, LVEF, QTc duration, BMI, and serum levels of troponin I 
and creatine kinase-MB. The strengths of the associations were substantially weaker after further adjustment for 
depressive disorder status, and the association was significant only for the composite MACE outcome.
Comparisons of first MACE rates by lower vs. higher methylation values stratified by baseline depressive dis-
order after adjustment are summarized in Table 4. Higher methylation was significantly associated with higher 
rates of composite MACE, all-cause mortality, cardiac death, and PCI only in those with depressive disorder after 
adjustment for age, ACS diagnosis, previous ACS, hypertension, diabetes, smoking, LVEF, QTc duration, BMI, 
and serum levels of troponin I and creatine kinase-MB. The NR3C1 methylation x depressive disorder multiplica-
tive interaction terms were statistically significant for the composite MACE, all-cause mortality, and cardiac death 
outcomes. Results of additional sensitivity analysis using the methylation percentages as a continuous variable 
and as tertials (lower, middle, and higher) are displayed in online Table S2 and online Table S3 respectively: in 
summary, the strengths of the associations were not substantially changed using continuous variables while the 
strength of the associations were generally lost but the significance of the association with MACE was remained 
in those with depressive disorder after adjustment. Model assumptions were all met (Schoenfeld p-values > 0.30).
Discussion
The principal findings from this cohort study were that higher NR3C1 methylation status was correlated with 
several cardiovascular risk markers at the early phase of ACS and predicted worse long-term prognosis. The 
longitudinal associations were significant only in the presence of depressive disorder with significant synergistic 
interaction terms, and were independent of a range of potential confounding factors.
In these patients with ACS, a higher NR3C1 methylation value was significantly correlated with worse profiles of 
several cardiovascular risk markers including QTc duration, BMI, and serum troponin I and CK-MB. These find-
ings are in line with recent studies reporting that hypermethylation of NR3C1 is associated with atherosclerosis11, 
and with heightened cardiovascular reactivity12. Although functional levels including GR mRNA or cortisol lev-
els were not measured in the present study, hypermethylation of the NR3C1 has been found to be related with 
reduced GR mRNA level8 and abnormal cortisol response22, which might affect glucocorticoid receptor sensitivi-
ties in turn cause endothelial dysfunctions, atherosclerosis and impaired metabolic signaling29,30. Based on these, 
it can be postulated that the association between NR3C1 hypermethylation and cardiovascular risk markers may 
underlie its deleterious effects on long-term prognosis of ACS. However, in the present study, the longitudinal 
associations were explained partially but not fully by these variables.
These prognostic effects were more strongly explained by depressive disorder status, in that they were signifi-
cant only in the presence of depressive disorder, independent of cardiovascular risk markers. Several explanations 
are possible for the observed synergistic effects. With respect to biological mechanisms, NR3C1 hypermethylation 
is associated with adverse profiles of cardiovascular risk markers as stated above. Added to this, depression itself 
rho P-value
Left ventricular ejection fraction, mean (SD) % −0.040 0.210
Wall motion, mean(SD) score +0.051 0.110
Heart rate, mean (SD) beats/min +0.057 0.079
PR interval, mean (SD) ms +0.054 0.090
QRS duration, mean (SD) ms +0.004 0.909
QTc duration, mean (SD) ms +0.069 0.036
Body mass index, mean (SD) Kg/m2 +0.073 0.025
Systolic blood pressure, mean (SD) mmHg −0.001 0.987
Diastolic blood pressure, mean (SD) mmHg +0.015 0.650
Troponin I, mean(SD) mg/dL +0.066 0.041
Creatine kinase-MB, mean(SD) mg/dL +0.066 0.040
Tumor necrosis factor-a, mean(SD) pg/mL +0.040 0.211
Interleukin-1b, mean(SD) pg/mL +0.009 0.779
Interleukin-6, mean(SD) pg/mL −0.009 0.770
Interleukin-18, mean(SD) pg/mL +0.018 0.574
High sensitivity C-reactive protein, mean(SD) mg/dL +0.050 0.123
Homocysteine, mean(SD) μmol/L −0.002 0.959
Total cholesterol, mean(SD) mg/dL +0.021 0.513
Lower density lipoprotein cholesterol, mean(SD) mg/dL +0.010 0.774
Triglyceride, mean(SD) mg/dL −0.007 0.845
Table 2. Spearman’s correlations between NR3C1 average methylation and cardiovascular risk markers at 
baseline partial for Beck Depression Index scores (N = 969).
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is associated with alterations in pro-inflammatory cytokines, and with autonomic and platelet dysfunction, which 
also have adverse effects on cardiac outcomes31,32; the synergy may therefore reflect multiple risk pathway involve-
ment. Considering behavioural aspects, NR3C1 methylation has functional influences affecting GR expression 
and finally dysregulating stress responses via HPA axis7–9, which may result in a reduced ability to cope with 
stressful situations such as unexpected ACS itself, financial and occupational problems, disabilities and other dif-
ficulties faced by patients with ACS. That is, ACS patients with NR3C1 hyper methylation, which was associated 
with cardiovascular risk markers, are more likely to also have depression. Moreover, depression has been asso-
ciated with unhealthy behaviors such as sedentary lifestyle, and irregular hospital visits and medication taking, 
Figure 1. Cumulative incidence (%) of composite major adverse cardiac events (MACE) by NR3C1 average 
methylation and depressive disorder at baseline.
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which themselves have negative effects on cardiac outcomes33. Summing up, ACS patients with both NR3C1 
hypermethylation and depressive disorder may be liable to poor prognosis through a combination of biological 
and behavioural factors.
As the first evaluation of these questions, this study has several strengths. Participants were consecutively 
recruited from all eligible patients with a recent ACS, which in turn contributed to decrease the risk of error orig-
inating from heterogeneous examination times and to increase the sample homogeneity. A depressive disorder 
was determined with a structured diagnostic interview, and psychiatric and cardiovascular characteristics were 
ascertained using well validated measurements. Vast amounts of covariates potentially affecting cardiac outcomes 
as well as methylation status were included in the present analyses. A single site recruitment was performed, 
which potentially results in a limitation of generalization of the present findings but possesses advantages in terms 
of consistency of evaluation and treatment. One important limitation of the present study is that only one CpG 
island in the NR3C1 gene was examined, although this area has been repeatedly investigated in previous epige-
netic studies pertaining to both depression and adverse life events22,24,34. Since this region was evaluated in rela-
tion to cardiac outcomes for the first time in our study, replication is needed. Attrition in the recruitment process 
can be another source of limitation because methylation analysis was available only in 84% of the baseline sam-
ples. However, no difference in the baseline demographic and clinical characteristics was found between patients 
with or without methylation analyses. Furthermore, long-term follow-up data on MACE have been completely 
collected for the primary analysis. Finial limitation was lack of functional measurement such as GR mRNA or 
cortisol levels. Although previous studies suggested that hypermethylation of NR3C1 methylation was associated 
with lower GR mRNA as well as abnormal cortisol response8,22, further investigations for underlying biological 
mechanisms between NR3C1 methylation and cardiac outcomes with interaction of depression.
In conclusion, higher NR3C1 methylation status at early phase of ACS predicted worse long-term prognosis 
of ACS in the presence of depressive disorder, independent of potential confounders including important cardio-
vascular risk markers. Similarly, associations of depression with worse long-term cardiac outcomes were stronger 
in ACS patients with higher NR3C1 methylation status. NR3C1 methylation tests might have clinical implications 
in screening for epigenetic susceptibility to identify high risk groups of poor ACS prognosis; therefore, this status 
serves as a promising prognostic biomarker in these patients particularly with the diagnosis of depressive disor-
ders. Future studies investigating the effects of drugs capable of regulating NR3C1 methylation on prognosis of 
ACS are anticipated, and the present study may serve as a foundation for future research.
N (%) MACE Hazard ratios (95% confidence intervals) [HRs (95% CIs)]
Lower methylation 
(N = 484)
Higher methylation 
(N = 485) Unadusted Adjusteda Adjustedb
MACE 166 (34.3) 217 (44.7) 1.48 (1.20–1.81)‡ 1.40 (1.14–1.71)† 1.25 (1.01–1.55)*
All-cause mortality 76 (15.7) 102 (21.0) 1.40 (1.04–1.89)* 1.35 (0.99–1.81) 1.24 (0.90–1.70)
Cardiac death 42 (8.7) 56 (11.5) 1.40 (0.94–2.11) 1.34 (0.90–1.99) 1.23 (0.80–1.88)
Myocardial infarction 41 (8.5) 60 (12.4) 1.51 (1.01–2.26)* 1.49 (1.99–2.19)* 1.17 (0.77–1.78)
Percutaneous coronary 
intervention 60 (12.4) 79 (16.3) 1.45 (1.03–2.04)* 1.38 (0.99–1.93) 1.24 (0.87–1.77)
Table 3. Associations of a higher NR3C1 average methylation at baseline with composite and individual 
components of major adverse cardiac events (MACE) in all patients with acute coronary syndrome (ACS). aModel 
1: adjusted for age, ACS diagnosis, previous ACS, hypertension, diabetes, smoking, left ventricular ejection 
fraction, QTc duration, body mass index, and serum levels of troponin I and creatine kinase-MB. bModel 2: 
additionally adjusted for depressive disorder status. *p-value < 0.05; †p-value < 0.01; ‡p-value < 0.001.
Absent depressive disorder (N = 591) Present depressive disorder (N = 378)
P-value for 
interaction
N (%) MACE
HRs (95% CIs)
N (%) MACE
HRs (95% CIs)
Lower 
methylation(N = 369)
Higher methylation 
(N = 222)
Lower methylation 
(N = 115)
Higher methylation 
(N = 263)
Composite MACE 122 (33.1) 64 (28.8) 0.97 (0.83–1.13) 44 (38.3) 153 (58.2) 1.98 (1.39–2.81)‡ 0.001
All-cause mortality 58 (15.7) 29 (13.1) 0.95 (0.76–1.20) 18 (15.7) 73 (27.8) 1.90 (1.12–3.22)* 0.013
Cardiac death 32 (8.7) 14 (6.3) 0.89 (0.64–1.22) 10 (8.7) 42 (16.0) 2.24 (1.09–4.59)* 0.036
Myocardial infarction 29 (7.9) 16 (7.2) 0.93 (0.69–1.27) 12 (10.4) 44 (16.7) 1.78 (0.92–3.46) 0.177
Percutaneous coronary 
intervention 43 (11.7) 23 (10.4) 0.95 (0.73–1.22) 17 (14.8) 56 (21.3) 1.90 (1.09–3.32)* 0.157
Table 4. Associations of a higher NR3C1 average methylation at baseline with composite and individual 
components of major adverse cardiac events (MACE) in patients with acute coronary syndrome (ACS) by 
depression depressive disorder status. Hazard ratio (95% confidence interval) [HR (95% CI)] was estimated 
with adjustment for age, ACS diagnosis, previous ACS, hypertension, diabetes, smoking, left ventricular ejection 
fraction, QTc duration, body mass index, and serum levels of troponin I and creatine kinase-MB at baseline. 
*p-value < 0.05; †p-value < 0.01; ‡p-value < 0.001.
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